oseltamivir has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Burov, SV; Haq, S; Harless, W; Markvicheva, E; Qorri, B; Sambi, M; Samuel, V; Szewczuk, MR | 1 |
1 other study(ies) available for oseltamivir and ER-Negative PR-Negative HER2-Negative Breast Cancer
Article | Year |
---|---|
A Triple Combination of Metformin, Acetylsalicylic Acid, and Oseltamivir Phosphate Impacts Tumour Spheroid Viability and Upends Chemoresistance in Triple-Negative Breast Cancer.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Apoptosis; Aspirin; Breast Neoplasms; CD24 Antigen; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Hyaluronan Receptors; Metformin; Oseltamivir; Retinal Dehydrogenase; Spheroids, Cellular; Tamoxifen; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2020 |